 |
Iroko Pharmaceuticals, LLC
Navy Yard Corporate Center
One Crescent Drive
Suite 400
Philadelphia, PA 19112
p 267.546.3003
f 267.546.3004
Contact Us
|
|
Chief Medical Officer Announces Intention to Retire
PHILADELPHIA, PA, March 10, 2008 — Susan F. Langer, M.D., Chief Medical Officer and Vice President, R&D, has announced her intention to retire from Iroko
Pharmaceuticals, LLC. Dr. Langer joined Iroko in May 2007, assisting in building and leading the Medical and R&D function.
Osagie Imasogie, Chairman of Iroko, stated: "When we founded and created Iroko last March, Susan agreed to delay her retirement from a distinguished career
in the pharmaceutical industry, to assist us in building a unique and successful specialty pharmaceutical company. With our successes over the past year,
Susan advised us that it is time to move forward on the transition and succession process. I know I am speaking for everyone at Iroko when I say that we are
deeply grateful for her service to Iroko and we will miss her judgment, experience, enthusiasm, and professionalism."
|
|
ALL PRESS RELEASES
New Data Shows Anticlotting Medicine, Tirofiban, Lowers Incidence of Heart Attack, in Patients Who Respond Poorly to Aspirin or Clopidogrel, After
Elective Coronary Angioplasty
09/02/2008
New Data Shows Acute Heart Attack Patients Given High-Dose Bolus (HDB) Tirofiban In-Ambulance, with Standard of Care,
Significantly Improves Clinical Outcomes
08/31/2008
iCeutica Completes GMP Scale-Up for its Nano-Sized Products
06/19/2008
Tirofiban Significantly Reduced Residual ST-Segment Deviation After Primary PCI in Patients with ST-Elevation Myocardial Infarction in Ongoing
Tirofiban in Myocardial Infarction Evaluation (On-TIME) 2 Trial
04/01/2008
High-Dose Tirofiban was as Effective as Abciximab in Reducing ST-Segment Elevation in STEMI Patients in the Multicentre
Evaluation of Single High-Dose Bolus Tirofiban versus Abciximab with Sirolimus Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study
03/30/2008
Chief Medical Officer Announces Intention to Retire
03/10/2008
Iroko Pharmaceuticals Acquires Rights to Cardiovascular Product from Merck & Co., Inc.
01/30/2008
Iroko Pharmaceuticals Acquires Canadian Rights to Lilly Anti-Infective Product
10/10/2007
Iroko Pharmaceuticals Acquires Nano-Reformulated Products from iCeutica
06/29/2007
Iroko Pharmaceuticals Appoints Susan F. Langer M.D. as Chief Medical Officer and Vice President of Research & Development
06/07/2007
Iroko Pharmaceuticals Appoints John Vavricka as President and Chief Executive Officer
04/18/2007
Iroko Pharmaceuticals Acquires Rights to Two Pharmaceutical Products from Merck & Company, Inc.
03/26/2007
|
